Update hepatitis (21 résultats)

Etat : New.

Etat : As New. Unread book in perfect condition.

Etat : As New. Unread book in perfect condition.

Etat : New.

Etat : New.

Taschenbuch. Etat : Neu. Update on the diagnosis of urinary tract infections | Diagnosis of diseases through urine reports diabetes mellitus, hepatitis, liver cirrhosis and pre-eclampsia | Aurora Martinez-Romero (u. a.) | Taschenbuch | Englisch | 2022 | Our Knowledge Publishing | EAN 9786204387420 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Etat : New.

Etat : New. In English.

Etat : New. Print on Demand.

Paperback / softback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.

Etat : New. Print on Demand.

Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The terms uroanalysis, urinalysis, urinalysis, urine analysis, urine cytochemistry, partial urinalysis describe a profile or group of screening tests capable of detecting renal, urinary tract or systemic disease. The urine test is performed in a simple and inexpensive way with strips and rapid reading equipment; it is a routine analysis for the study of patients with alterations in urinary tract, it is a test that provides indicators for the study of the health-disease process. It analyzes the microscopic characteristics of the urinary sediment, which verifies hematuria, pyuria, cylindruria, crystalluria. The general urine test is not only a routine test, but it is a study that helps the doctor to diagnose various pathologies and infections and make the most of the test in clinical practice, also the general urine test is a low cost test that if carried out accurately and properly will provide great useful information to the doctor and thus prevent in time some pathologies of the urinary system that may occur in the patient.…

Etat : New. PRINT ON DEMAND.

Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska; Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology; Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B; Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B; Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents; Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment-- the most dreadful outcome of this disease; Dr. Paul Martin discusses management of end- stage chronic hepatitis B -anti-viral therapy, montherapy vs combo.therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection; Dr. Tram Tran discuss the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents-- an area with significant lack of good clinical evidence; Dr. Steve Han discuss management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection; Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma; and finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease. 171 pp. Englisch.…

Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska; Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology; Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B; Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B; Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents; Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment-- the most dreadful outcome of this disease; Dr. Paul Martin discusses management of end- stage chronic hepatitis B -anti-viral therapy, montherapy vs combo.therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection; Dr. Tram Tran discuss the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents-- an area with significant lack of good clinical evidence; Dr. Steve Han discuss management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection; Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma; and finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.…

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Gebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. KlappentextrnrnIn the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability.…

Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options. 238 pp. Englisch.…

Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.Books on Demand GmbH, Überseering 33, 22297 Hamburg 238 pp. Englisch.…

Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.…